These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24850453)

  • 1. [Impacts of new agents for multiple myeloma on development of secondary myelodysplastic syndrome and acute myeloid leukemia].
    Hamano A; Shingaki S; Abe Y; Miyazaki K; Sekine R; Nakagawa Y; Tsukada N; Hattori Y; Suzuki K
    Rinsho Ketsueki; 2014 Apr; 55(4):428-35. PubMed ID: 24850453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents.
    Gertz MA; Terpos E; Dispenzieri A; Kumar S; Shah RA; Orlowski R; Kastritis E; Dimopoulos MA; Shah J
    Leuk Lymphoma; 2015 Jun; 56(6):1723-6. PubMed ID: 25284489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
    Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
    Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.
    Palumbo A; Bringhen S; Rossi D; Cavalli M; Larocca A; Ria R; Offidani M; Patriarca F; Nozzoli C; Guglielmelli T; Benevolo G; Callea V; Baldini L; Morabito F; Grasso M; Leonardi G; Rizzo M; Falcone AP; Gottardi D; Montefusco V; Musto P; Petrucci MT; Ciccone G; Boccadoro M
    J Clin Oncol; 2010 Dec; 28(34):5101-9. PubMed ID: 20940200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
    Usmani SZ; Sawyer J; Rosenthal A; Cottler-Fox M; Epstein J; Yaccoby S; Sexton R; Hoering A; Singh Z; Heuck CJ; Waheed S; Chauhan N; Johann D; Abdallah AO; Muzaffar J; Petty N; Bailey C; Crowley J; van Rhee F; Barlogie B
    Blood; 2013 Jun; 121(23):4753-7. PubMed ID: 23603914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current therapeutic strategy for multiple myeloma.
    Suzuki K
    Jpn J Clin Oncol; 2013 Feb; 43(2):116-24. PubMed ID: 23293370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
    Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
    Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytogenetic abnormalities in acute leukemia complicating melphalan-treated multiple myeloma.
    Rödjer S; Swolin B; Weinfeld A; Westin J
    Cancer Genet Cytogenet; 1990 Aug; 48(1):67-73. PubMed ID: 2372790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
    Palumbo A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Levi A; Benevolo G; Vincelli ID; Grasso M; Franceschini L; Gottardi D; Zambello R; Montefusco V; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; Cavo M
    J Clin Oncol; 2014 Mar; 32(7):634-40. PubMed ID: 24449241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
    San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Delforge M; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Deraedt W; Cakana A; van de Velde H; Richardson PG
    J Clin Oncol; 2013 Feb; 31(4):448-55. PubMed ID: 23233713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.
    Terpos E; Kastritis E; Roussou M; Heath D; Christoulas D; Anagnostopoulos N; Eleftherakis-Papaiakovou E; Tsionos K; Croucher P; Dimopoulos MA
    Leukemia; 2008 Dec; 22(12):2247-56. PubMed ID: 18769451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma.
    El-Cheikh J; Stoppa AM; Bouabdallah R; de Lavallade H; Coso D; de Collela JM; Auran-Schleinitz T; Gastaut JA; Blaise D; Mohty M
    Clin Lymphoma Myeloma; 2008 Jun; 8(3):146-52. PubMed ID: 18650177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myeloma and second primary cancers.
    Landgren O; Thomas A; Mailankody S
    N Engl J Med; 2011 Dec; 365(23):2241-2. PubMed ID: 22150057
    [No Abstract]   [Full Text] [Related]  

  • 14. Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital.
    Teh BW; Worth LJ; Harrison SJ; Thursky KA; Slavin MA
    Support Care Cancer; 2015 Jul; 23(7):1901-6. PubMed ID: 25487843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy.
    Koeppen S
    Oncol Res Treat; 2014; 37(9):506-13. PubMed ID: 25231692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thrombotic complications following the treatment of multiple myeloma with new agents].
    Rupa-Matysek J; Gil L; Komarnicki M
    Pol Merkur Lekarski; 2011 Dec; 31(186):372-7. PubMed ID: 22239010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
    Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
    Morabito F; Bringhen S; Larocca A; Wijermans P; Victoria Mateos M; Gimsing P; Mazzone C; Gottardi D; Omedè P; Zweegman S; José Lahuerta J; Zambello R; Musto P; Magarotto V; Schaafsma M; Oriol A; Juliusson G; Cerrato C; Catalano L; Gentile M; Isabel Turel A; Marina Liberati A; Cavalli M; Rossi D; Passera R; Rosso S; Beksac M; Cavo M; Waage A; San Miguel J; Boccadoro M; Sonneveld P; Palumbo A; Offidani M
    Am J Hematol; 2014 Apr; 89(4):355-62. PubMed ID: 24273190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of older patients with multiple myeloma.
    Gay F; Palumbo A
    Blood Rev; 2011 Mar; 25(2):65-73. PubMed ID: 21295387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide.
    Satoh M; Oguro R; Yamanaka C; Takada K; Matsuura Y; Akiba T; Aotsuka N; Tani Y; Wakita H
    J Pharm Pharm Sci; 2011; 14(1):78-89. PubMed ID: 21501555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.